This is a prospective, multicentre observational study screening all adult patients admitted to a participating hospital over a 6-month study period (may be adjusted to 4-8 months according to recruitment) and including all patients with suspicion of or confirmed acute mesenteric ischaemia (AMI). Only admission data and hospital mortality outcome will be collected for patients in whom suspicion of AMI is not confirmed. For patients with confirmed AMI full data collection regarding diagnostics, management and long-term outcome is required. Investigators aim to recruit 40-50 sites with expected median of 10-20 patients with confirmed AMI per site during the study period (naturally depending on the size of the hospital). The start of the study is planned for Spring 2022. The aim of the study is to identify the incidence of AMI and its different forms in adult hospitalized patients, and to describe patient characteristics (demographic, clinical and laboratory) at baseline, applied diagnostics and management, as well as outcomes in patients with AMI. An additional aim is to compare the baseline characteristics and outcomes of patients with confirmed AMI to those of patients with suspected AMI in whom the diagnosis was not confirmed.
Study Type
OBSERVATIONAL
Enrollment
709
No intervention
North Estonian Regional Hospital
Tallinn, Estonia
Tartu University Hospital
Tartu, Estonia
Kantonsspital Luzern
Lucerne, Switzerland
Incidence of AMI
Incidence of AMI in hospitalized adult patients in acute care hospitals
Time frame: 6 months
30 days survival of AMI
survival of patients with confirmed AMI
Time frame: 30 days after admission/suspicion of AMI/study inclusion
Proportion of different forms of AMI
Proportion of each form of AMI from all AMI cases
Time frame: 6 months
Time to diagnosis
Time from symptoms to diagnosis
Time frame: through study completion, study duration 6 months
Time to treatment
Time from diagnosis to treatment
Time frame: through study completion, study duration 6 months
Treatment
Surgery, endovascular intervention or palliation
Time frame: through study completion, study duration 6 months
1 year survival
Survival of patients with AMI 1 year after diagnosis
Time frame: 1 year
Quality of life score
EQ-5D-5L (EuroQoL - European Quality of Life ), 5-25 points, the lower score means better outcome
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.